Oliver Sartor
Overview
Explore the profile of Oliver Sartor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
427
Citations
10288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Naqvi S, Riaz I, Bibi A, Khan M, Imran M, Rubab Khakwani K, et al.
Eur Urol
. 2025 Jan;
PMID: 39848867
Background And Objective: Selection of patients harboring mutations in homologous recombination repair (HRR) genes for treatment with a PARP inhibitor (PARPi) is challenging in metastatic castration-resistant prostate cancer (mCRPC). To...
2.
Hansen A, Probst S, Beauregard J, Viglianti B, Michalski J, Tagawa S, et al.
Front Oncol
. 2025 Jan;
14():1483953.
PMID: 39839782
Introduction: SPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase...
3.
OSullivan J, Heinrich D, Castro E, George S, Dizdarevic S, Baldari S, et al.
Br J Cancer
. 2025 Jan;
132(4):354-360.
PMID: 39789153
Background: Alkaline phosphatase (ALP) declines and pain responses can occur during radium-223 (Ra) treatment, but their association with treatment outcomes is unclear. Methods: For patients with metastatic castration-resistant prostate cancer...
4.
Hwang J, Likasitwatanakul P, Deshmukh S, Wu S, Kwon J, Toye E, et al.
Clin Cancer Res
. 2025 Jan;
31(5):936-948.
PMID: 39745364
Purpose: Around 10% to 15% of prostate cancers harbor recurrent aberrations in the Forkhead Box A1 gene, FOXA1, whereby the alteration type and the effect on the forkhead (FKH) domain...
5.
Shore N, Nielsen S, Esplin E, Antonarakis E, Barata P, Beer T, et al.
JCO Oncol Pract
. 2024 Dec;
OP2400626.
PMID: 39700441
Indications for and implications of germline genetic testing (GGT) in patients with prostate cancer have expanded over the past decade, particularly related to precision therapies and management. GGT has become...
6.
Bryce A, Agarwal N, Beltran H, Hussain M, Sartor O, Shore N, et al.
Cancer
. 2024 Dec;
131(1):e35612.
PMID: 39616467
Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions...
7.
Muniz M, Sartor O, Orme J, Koch R, Rosenow H, Mahmoud A, et al.
J Nucl Med
. 2024 Oct;
65(12):1932-1938.
PMID: 39477495
It is well known that patients with liver metastasis from metastatic castration-resistant prostate cancer have poor or only transient responses to many forms of systemic therapy. Data on outcomes after...
8.
Bilgin G, Navin P, Johnson D, Sartor O, Kendi A
Front Oncol
. 2024 Oct;
14:1442293.
PMID: 39435291
Radioligand therapies such as [Lu] Lu-PSMA-617 have gained significant momentum in cancer treatment after clinical trials and multicenter studies demonstrated their safety and efficacy. As these innovative treatments become more...
9.
Herrmann K, Gafita A, de Bono J, Sartor O, Chi K, Krause B, et al.
EClinicalMedicine
. 2024 Oct;
77:102862.
PMID: 39430616
Background: [Lu]Lu-PSMA-617 (Lu-PSMA-617) prolonged life in patients with metastatic castration-resistant prostate cancer (mCRPC) in VISION (NCT03511664). However, distinguishing between patients likely and unlikely to respond remains a clinical challenge. We...
10.
Sollini M, Calais J, Chiti A, Emmett L, Fanti S, Fendler W, et al.
Eur Urol
. 2024 Oct;
87(2):125-139.
PMID: 39428326
Background And Objective: This review aims to provide an overview of novel diagnostic and therapeutic radiopharmaceuticals tested recently or used currently in genitourinary cancers within prospective phase 1-2 clinical trials,...